Venture Capital

Baker Donelson's Venture Capital Group provides sophisticated counsel to both venture capital and private equity funds and to emerging companies seeking venture capital financing. We represent venture capital clients in their formation and fund raising activities, as well as with all phases of their venture investment activities. We also represent emerging companies who seek venture capital financing as a means to expand their business or exploit other opportunities. With our balanced experience representing both constituents in the venture capital community, we have developed a thorough understanding of the issues and concerns of all parties in a venture capital financing.

Baker Donelson's representation of venture capital and other private equity funds has included funds focused on specific business plans such as biotechnology, to funds focused on specific investment strategies such as mezzanine capital. Our representation of these clients has given us an intimate understanding of private equity funds, their goals and their limitations. We utilize Firm specialists in the critical areas of securities, tax, ERISA, intellectual property and banking regulatory fields to ensure that we have addressed every important issue.

Representative Matters

  • Photographic film processor — $2 million mezzanine capital investment
  • Environmental remediation company — $2 million of Series A preferred stock
  • Software technology company — $2 million of preferred stock to angel investors
  • Restaurant brewery company — Sale of $23 million of mezzanine notes and $12.5 million of Series B and Series C stock
  • Internet provider of medical supplies and equipment to hospitals — Private placement of preferred stock to venture capital funds and private investors
  • Medical imaging company — Private placement of preferred stock to venture capital funds
  • Independent filmmaker — Private placement of equity to fund production and distribution of two documentary films
  • Venture capital firms — Facilitated investment in software development and biotechnology startup companies
  • Represented wastewater treatment company in connection with fund raising and general business matters
  • Assisted in $10 million of investments by a client venture capital fund in six companies (March 2002 through July 2003)

Private Equity Fund Representation

  • Private equity fund — Organization of fund and $12 million private placement offering
  • Private equity fund — $15 million mezzanine capital fund
  • Private equity fund — $30 million mezzanine capital fund
  • Private equity fund — $1.5 million mezzanine capital investment
  • Biotechnology venture fund — $25 million capital raise
  • Biotechnology venture fund — $10 million of multiple investments in target industry